246 related articles for article (PubMed ID: 35490795)
1. Induction of ferroptosis by carnosic acid-mediated inactivation of Nrf2/HO-1 potentiates cisplatin responsiveness in OSCC cells.
Han L; Li L; Wu G
Mol Cell Probes; 2022 Aug; 64():101821. PubMed ID: 35490795
[TBL] [Abstract][Full Text] [Related]
2. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling.
Fu D; Wang C; Yu L; Yu R
Cell Mol Biol Lett; 2021 Jun; 26(1):26. PubMed ID: 34098867
[TBL] [Abstract][Full Text] [Related]
3. Nrf2/HO-1 Alleviates Disulfiram/Copper-Induced Ferroptosis in Oral Squamous Cell Carcinoma.
Zhao Y; Zhu S
Biochem Genet; 2024 Feb; 62(1):144-155. PubMed ID: 37286868
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
5. Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma.
Zhao B; Qin X; Fu R; Yang M; Hu X; Zhao S; Cui Y; Guo Q; Zhou W
J Control Release; 2024 Apr; 368():623-636. PubMed ID: 38479445
[TBL] [Abstract][Full Text] [Related]
6. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
7. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
8. Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer.
Lou JS; Zhao LP; Huang ZH; Chen XY; Xu JT; Tai WC; Tsim KWK; Chen YT; Xie T
Phytomedicine; 2021 Jan; 80():153370. PubMed ID: 33113504
[TBL] [Abstract][Full Text] [Related]
9. The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin.
Liu Q; Wang K
Cell Biol Int; 2019 Nov; 43(11):1245-1256. PubMed ID: 30811078
[TBL] [Abstract][Full Text] [Related]
10. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
[TBL] [Abstract][Full Text] [Related]
11. Oxysophocarpine Retards the Growth and Metastasis of Oral Squamous Cell Carcinoma by Targeting the Nrf2/HO-1 Axis.
Liu R; Peng J; Wang H; Li L; Wen X; Tan Y; Zhang L; Wan H; Chen F; Nie X
Cell Physiol Biochem; 2018; 49(5):1717-1733. PubMed ID: 30231242
[TBL] [Abstract][Full Text] [Related]
12. HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway.
Zhu R; Mao Y; Xu X; Li Y; Zheng J
Anticancer Drugs; 2024 Jul; 35(6):492-500. PubMed ID: 38477942
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis.
Wang J; Jia J; Zhou L
Neoplasma; 2020 Nov; 67(6):1279-1292. PubMed ID: 32787433
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of HDAC6 overcomes cisplatin chemoresistance by targeting cancer stem cells in oral squamous cell carcinoma.
Tavares MO; Milan TM; Bighetti-Trevisan RL; Leopoldino AM; de Almeida LO
J Oral Pathol Med; 2022 Jul; 51(6):529-537. PubMed ID: 35678235
[TBL] [Abstract][Full Text] [Related]
15. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
16. GAS5 alleviates cisplatin drug resistance in oral squamous cell carcinoma by sponging miR-196a.
Yuan X; Jing Y; Guang M; Zhu J; Wang J; Wang Y; Zhang Y
J Int Med Res; 2022 Oct; 50(10):3000605221132456. PubMed ID: 36310502
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of TNF-alpha/NFkB/SIRT1 axis drives aggressiveness and cancer stem cells accumulation in chemoresistant oral squamous cell carcinoma.
de Castro LR; de Oliveira LD; Milan TM; Eskenazi APE; Bighetti-Trevisan RL; de Almeida OGG; Amorim MLM; Squarize CH; Castilho RM; de Almeida LO
J Cell Physiol; 2024 Feb; 239(2):e31164. PubMed ID: 38149816
[TBL] [Abstract][Full Text] [Related]
18. An Acid-Responsive Iron-Based Nanocomposite for OSCC Treatment.
Zhao X; Leng D; Wang H; Jin H; Wu Y; Qin Z; Wu D; Wei X
J Dent Res; 2024 Jun; 103(6):612-621. PubMed ID: 38684484
[TBL] [Abstract][Full Text] [Related]
19. Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.
Wu YC; Huang CS; Hsieh MS; Huang CM; Setiawan SA; Yeh CT; Kuo KT; Liu SC
Aging (Albany NY); 2024 Jan; 16(1):627-647. PubMed ID: 38206305
[TBL] [Abstract][Full Text] [Related]
20. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
Zhang Y; Tan Y; Liu S; Yin H; Duan J; Fan L; Zhao X; Jiang B
Toxicol Mech Methods; 2023 Jan; 33(1):47-55. PubMed ID: 35592903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
